Thangirala Sudha - Search Results

Year	Number of Results
2002	1
2008	1
2009	3
2010	1
2012	2
2013	2
2014	3
2015	4
2016	4
2017	5
2019	2
2020	6
2021	11
2022	5
2023	2
2024	0

1

Thyroid Hormone, Hormone Analogs, and Angiogenesis.

Davis PJ, Sudha T, Lin HY, Mousa SA. Davis PJ, et al. Among authors: sudha t. Compr Physiol. 2015 Dec 15;6(1):353-62. doi: 10.1002/cphy.c150011. Compr Physiol. 2015. PMID: 26756636 Review.

2

Thyroid hormone and P-glycoprotein in tumor cells.

Davis PJ, Incerpi S, Lin HY, Tang HY, Sudha T, Mousa SA. Davis PJ, et al. Among authors: sudha t. Biomed Res Int. 2015;2015:168427. doi: 10.1155/2015/168427. Epub 2015 Mar 19. Biomed Res Int. 2015. PMID: 25866761 Free PMC article. Review.

3

Characterization of tryptophan-containing dipeptides for anti-angiogenic effects.

Khedr S, Klotzsche-von Ameln A, Khedr M, Elsayed MH, Sudha T, Mousa SA, Deussen A, Martin M. Khedr S, et al. Among authors: sudha t. Acta Physiol (Oxf). 2021 Feb;231(2):e13556. doi: 10.1111/apha.13556. Epub 2020 Sep 15. Acta Physiol (Oxf). 2021. PMID: 32894635

4

Antitumor/anti-angiogenesis efficacy of epigallocatechin gallate nanoformulated with antioxidant in melanoma.

Sudha T, Salaheldin TA, Darwish NH, Mousa SA. Sudha T, et al. Nanomedicine (Lond). 2022 Jun;17(15):1039-1053. doi: 10.2217/nnm-2021-0362. Epub 2022 Sep 14. Nanomedicine (Lond). 2022. PMID: 36102916

5

Editorial Expression of Concern: Response of human pancreatic cancer cell xenografts to tetraiodothyroacetic acid nanoparticles.

Yalcin M, Lin HY, Sudha T, Bharali DJ, Meng R, Tang HY, Davis FB, Stain SC, Davis PJ, Mousa SA. Yalcin M, et al. Among authors: sudha t. Discov Oncol. 2023 May 22;14(1):75. doi: 10.1007/s12672-023-00668-5. Discov Oncol. 2023. PMID: 37213035 Free PMC article. No abstract available.

6

Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesis.

Davis PJ, Lin HY, Sudha T, Yalcin M, Tang HY, Hercbergs A, Leith JT, Luidens MK, Ashur-Fabian O, Incerpi S, Mousa SA. Davis PJ, et al. Among authors: sudha t. Onco Targets Ther. 2014 Sep 18;7:1619-24. doi: 10.2147/OTT.S67393. eCollection 2014. Onco Targets Ther. 2014. PMID: 25258542 Free PMC article. Review.

7

Nano-Targeting of Thyrointegrin αvβ3 Receptor in Solid Tumors and Impact on Radiosensitization.

Sudha T, Rehman MU, Darwish NHE, Coskun MD, Satti JA, Davis PJ, Mousa SA. Sudha T, et al. Radiat Res. 2021 Oct 1;196(4):375-385. doi: 10.1667/RADE-21-00031.1. Radiat Res. 2021. PMID: 34260732

8

Targeting Thyrointegrin αvβ3 Using Fluorobenzyl Polyethylene Glycol Conjugated Tetraiodothyroacetic Acid (NP751) in Acute Myeloid Leukemia.

Darwish NHE, Glinsky GV, Sudha T, Mousa SA. Darwish NHE, et al. Among authors: sudha t. Front Oncol. 2022 Jan 27;11:793810. doi: 10.3389/fonc.2021.793810. eCollection 2021. Front Oncol. 2022. PMID: 35155195 Free PMC article.

9

New Thyrointegrin α_vβ₃ Antagonist with a Scalable Synthesis, Brain Penetration, and Potent Activity against Glioblastoma Multiforme.

Hay BA, Godugu K, Darwish NHE, Fujioka K, Sudha T, Karakus OO, Mousa SA. Hay BA, et al. Among authors: sudha t. J Med Chem. 2021 May 13;64(9):6300-6309. doi: 10.1021/acs.jmedchem.1c00350. Epub 2021 Apr 22. J Med Chem. 2021. PMID: 33886292

10

Nanoparticulate Tetrac Inhibits Growth and Vascularity of Glioblastoma Xenografts.

Sudha T, Bharali DJ, Sell S, Darwish NHE, Davis PJ, Mousa SA. Sudha T, et al. Horm Cancer. 2017 Jun;8(3):157-165. doi: 10.1007/s12672-017-0293-6. Epub 2017 Apr 10. Horm Cancer. 2017. PMID: 28396979 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

46 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year